Inmed Pharmaceuticals Inc Revenue Growth Rates (INM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Inmed Pharmaceuticals Inc  (NASDAQ: INM)
 

INM's Revenue Growth by Quarter and Year

Inmed Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INM Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter June 0.00
3rd Quarter March 0.00
2nd Quarter December 0.82
1st Quarter September 1.12
FY 1.94

INMs Annual Revenue
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2026 $ 0.00 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 4.94 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 1.17 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 4.14 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 1.09 millions




INM Revenue fourth quarter 2023 Y/Y Growth Comment
Inmed Pharmaceuticals Inc in the fourth quarter 2023 recorded of $ 0.00 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Inmed Pharmaceuticals Inc' s Revenue meltdown of -100% ranks overall at the positon no. 1287 in the fourth quarter 2023.


INM Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter June - 47.73 % -14.56 % 232.26 %
3rd Quarter March - 1.61 % 163.83 % 74.07 %
2nd Quarter December -26.13 % 23.33 % 181.25 % -
1st Quarter September -11.11 % -45.45 % 352.94 % -42.05 %
FY   -60.65 % -7.5 % 128.76 % -

Financial Statements
Inmed Pharmaceuticals Inc's fourth quarter 2023 Revenue $ 0.00 millions INM's Income Statement
Inmed Pharmaceuticals Inc's fourth quarter 2022 Revenue $ 1.30 millions Quarterly INM's Income Statement


INM Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter June - 3.17 % -29.03 % 119.15 %
3rd Quarter March - 13.51 % 37.78 % 46.87 %
2nd Quarter December -26.79 % -11.9 % -61.04 % -37.25 %
1st Quarter September -13.85 % 43.18 % 124.27 % 64.52 %
FY (Year on Year)   -60.65 % -7.5 % 128.76 % -


Back to INM Growth rate Comparisons >> Back to INM Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #275
Overall #1287

Revenue Y/Y Growth Statistics
High Average Low
239.77 % 65.36 % -17.71 %
(Dec 31 2023)   (Mar 31 2025)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #275
Overall #1287
Revenue Y/Y Growth Statistics
High Average Low
239.77 % 65.36 % -17.71 %
(Dec 31 2023)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Inmed Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INM's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INM's IV. Quarter Q/Q Revenue Comment


Inmed Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 4.51 $ 4.80 $ 4.94
Y / Y Revenue Growth (TTM) - - 0.28 % 12 % -7.28 %
Year on Year Revenue Growth Overall Ranking # 2936 # 3398 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) - - -6.08 % -2.92 % 9.46 %
Seq. Revenue Growth (TTM) Overall Ranking # 1287 # 872 # 863 # 0 # 130


Cumulative Revenue growth Comment
Inmed Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 447 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2936, from total ranking in previous quarter at 3398.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 448
Overall # 2936

Revenue TTM Y/Y Growth Statistics
High Average Low
239.77 %
 65.36 %
-17.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 275
S&P 500 # 1287
Cumulative Revenue growth Comment
Inmed Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 447 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2936, from total ranking in previous quarter at 3398.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 448
Overall # 2936

Revenue TTM Y/Y Growth Statistics
High Average Low
239.77 %
65.36 %
-17.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 275
S&P 500 # 1287




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Inmed Pharmaceuticals Inc Revenue Growth Rates (INM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Inmed Pharmaceuticals Inc (CIK 1728328).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-098419
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Inmed Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.